Catalysts for Novo Nordisk Inc

Liraglutide Injection shortage — Novo Nordisk, Inc.

SAXENDA (LIRAGLUTIDE) — FDA approval

LIRAGLUTIDE — FDA approval

LIRAGLUTIDE — FDA approval

LIRAGLUTIDE — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval

LIRAGLUTIDE — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

XULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approval

SAXENDA (LIRAGLUTIDE) — FDA approval